VANCOUVER and MINNEAPOLIS, April 28, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced progress towards its value creation strategy of expanding global reimbursement for the Neovasc Reducer™ (“Reducer”). Expanding reimbursement for the Reducer is a key component of Neovasc’s strategy to create shareholder value. In […]
Other News
Quantum Genomics Secures €3 Million Non-dilutive Financing
€1.5 million guaranteed by the French government (PGE) and granted by BNP bank €1.5 million innovation and R&D loan granted by Bpifrance Funding will allow for acceleration of R&D programs PARIS, April 28, 2021 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the […]
CMS Proposes Additional Payment for Shockwave’s Coronary IVL in Hospital Inpatient Cases
New Technology Add-on Payment (NTAP) Included in Proposed Fiscal Year 2022 Rule SANTA CLARA, CALIF., April 27, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the Centers for Medicare and Medicaid […]
Improved Clinical Outcomes for Heart Transplant Recipients Announced From International Study on Paragonix SherpaPak® CTS
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies announced the presentation of the First Report of the GUARDIAN Registry1 at the International Society for Heart and Lung Transplantation 2021 Annual Meeting. The GUARDIAN study is the largest multi-center, international registry specifically focused on donor heart preservation. Clinical investigators from the first five enrolling centers collaborated to pool their data and […]
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment
CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or are at high risk for hyperkalemia (HK), in Europe and the US CARE-HK in HF is designed to evaluate the use of Veltassa® in enabling patients to remain on RAASi therapy […]
Dr. Paula A. Johnson Joins Abiomed Board of Directors
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately. Dr. Johnson will serve as a member of the Governance and Nominating Committee of the board. Following the appointment of Dr. Johnson, the board now comprises nine active directors. “Dr. […]
BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia
CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing BRUKINSA® (zanubrutinib) against ibrutinib in adults with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). BRUKINSA met the primary endpoint of the […]
Connect For Education and Starting Hearts Announce the Launch of their Powerful Online Education Program and Training Platform
Online Training Course Aims to Improve Outcomes for Sudden Cardiac Arrest Victims HERNON, Va., April 27, 2021 /PRNewswire/ — Connect For Education Inc. (C4E), a leading provider of online education technologies, is proud to announce a successful launch of Call.Push.Shock, a highly-interactive online training and education curriculum that provides users of all ages […]
Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal
– First-of-its-kind outcomes trial designed to assess cardiovascular risk reduction in patients with documented intolerance to statin therapy – – Nearly half of trial participants are women, a significantly higher proportion than have been included in any other previous cardiovascular outcomes study in history – – Event driven MACE (major […]
CHF Solutions Expands Commercial Focus, Changes Name to Nuwellis
The new name reflects the company’s commitment to pediatric, critical care, and chronic heart failure patients EDEN PRAIRIE, Minn., April 27, 2021 (GLOBE NEWSWIRE) — Company names are reflective of the services provided to its customers, and CHF Solutions – a leader and pioneer in the heart failure space – […]



